<DOC>
	<DOCNO>NCT01778803</DOCNO>
	<brief_summary>This Phase I/Ib , open-label , multicenter , dose-escalation trial paclitaxel combination defactinib ( VS-6063 ) , focal adhesion kinase inhibitor , patient advance ovarian cancer . This clinical study comprise 2 part : Phase I ( Dose Escalation ) Phase Ib ( Expansion ) . The purpose study assess ass safety ( include recommend phase 2 dose ) , pharmacokinetics , anti-cancer activity defactinib ( VS-6063 ) administer combination paclitaxel . Pharmacodynamic effect also examine tumor biopsy .</brief_summary>
	<brief_title>Phase I/Ib Study Paclitaxel Combination With VS-6063 Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Able provide sign date informed consent prior initiation study procedure . 2 . Female subject age ≥ 18 year . 3 . Advanced refractory ovarian cancer , confirm histologically . 4 . Subjects may receive 4 prior line chemotherapy metastatic disease . 5 . All persistent clinically significant toxicity prior chemotherapy must ≤ Grade 1 . 6 . ECOG performance status 0 1 ( refer Appendix A ) , measure within 72 hour start treatment . 7 . Predicted life expectancy ≥ 3 month . 8 . Adequate renal function [ creatinine ≤ 1.5x ULN ( upper limit normal ) ] GFR ≥ 50mL/min . 9 . Adequate hepatic function ( total bilirubin ≤ 1.5x ULN institution ; AST [ aspartate transaminase ] ALT [ alanine transaminase ] ≤ 3x ULN , ≤ 5x ULN due liver involvement tumor ) . 10 . Adequate bone marrow function ( hemoglobin ≥ 9.0 g/dL ; platelets≥ 100 x109cells/L ; absolute neutrophil count ≥ 1.5x109 cells/L ) . 11 . Corrected QT interval ( QTc ) &lt; 470 m ( calculate Fridericia correction formula ) . 12 . Negative pregnancy test female childbearing potential ; must surgically sterile , postmenopausal , willing able compliant contraceptive regimen ( double barrier birth control ) 3 month treatment period . 13 . Willing able participate trial comply trial requirement . 1 . Gastrointestinal ( GI ) condition could interfere swallow absorption study medication . 2 . Uncontrolled severe concurrent medical condition ( include uncontrolled brain metastasis ) . Stable brain metastasis either treat treat stable dose steroids/anticonvulsants , dose change within 28 day prior first dose study drug , allow . 3 . History upper gastrointestinal bleeding , ulceration , perforation within 12 month prior first dose study drug . 4 . Known history Gilbert 's Syndrome . 5 . Known history stroke cerebrovascular accident within 6 month prior first dose study drug . 6 . Subjects know infection human immunodeficiency virus ( HIV ) Acquired Immune Deficiency Syndrome ( AIDS ) ( test require ) . 7 . Subjects Hepatitis A , B C ( test require ) . 8 . Subjects actively treat secondary malignancy . 9 . Cancerdirected therapy ( chemotherapy , radiotherapy , hormonal therapy , biologic immunotherapy , etc . ) within 28 day first dose study drug 5 halflives , whichever short . 10 . Major surgery within 28 day prior first dose study drug . 11 . Use investigational drug within 28 day 5 halflives ( whichever short ) prior first dose study drug . A minimum 10 day termination investigational drug administration study treatment require . In addition , drugrelated toxicity except alopecia recover grade 1 less . 12 . Pregnant breastfeeding . 13 . Any evidence serious active infection . 14 . Uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease , cardiac amyloidosis . 15 . Uncontrolled intercurrent illness include symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>